Free Trial
NASDAQ:HBIO

Harvard Bioscience (HBIO) Stock Price, News & Analysis

Harvard Bioscience logo
$0.47 -0.02 (-3.11%)
Closing price 04:00 PM Eastern
Extended Trading
$0.48 +0.00 (+0.21%)
As of 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Harvard Bioscience Stock (NASDAQ:HBIO)

Key Stats

Today's Range
$0.47
$0.50
50-Day Range
$0.40
$0.57
52-Week Range
$0.28
$3.04
Volume
376,606 shs
Average Volume
4.81 million shs
Market Capitalization
$21.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
Consensus Rating
Moderate Buy

Company Overview

Harvard Bioscience Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
83rd Percentile Overall Score

HBIO MarketRank™: 

Harvard Bioscience scored higher than 83% of companies evaluated by MarketBeat, and ranked 149th out of 650 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Harvard Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Harvard Bioscience has received no research coverage in the past 90 days.

  • Read more about Harvard Bioscience's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Harvard Bioscience is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Harvard Bioscience is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Harvard Bioscience has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Harvard Bioscience's valuation and earnings.
  • Percentage of Shares Shorted

    1.56% of the float of Harvard Bioscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Harvard Bioscience has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Harvard Bioscience has recently decreased by 55.14%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Harvard Bioscience does not currently pay a dividend.

  • Dividend Growth

    Harvard Bioscience does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.56% of the float of Harvard Bioscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Harvard Bioscience has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Harvard Bioscience has recently decreased by 55.14%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Harvard Bioscience has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Computer and Technology companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Harvard Bioscience this week, compared to 16 articles on an average week.
  • Search Interest

    3 people have searched for HBIO on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Harvard Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Harvard Bioscience insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.50% of the stock of Harvard Bioscience is held by insiders.

  • Percentage Held by Institutions

    80.87% of the stock of Harvard Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Harvard Bioscience's insider trading history.
Receive HBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harvard Bioscience and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HBIO Stock News Headlines

Harvard Bioscience (NASDAQ:HBIO) Cut to Hold at Wall Street Zen
What's the Best Way to Lower RMD Taxes?
Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain retirement accounts. Without the right strategy, these withdrawals can significantly increase your tax bill and shrink your nest egg. SmartAsset outlines six strategies that could help reduce your RMDs and potentially lower your tax burden. Their free tool can match you with vetted fiduciary financial advisors in your area—professionals legally bound to act in your best interest.tc pixel
Harvard Bioscience Offers CFO $100K Retention Bonus
See More Headlines

HBIO Stock Analysis - Frequently Asked Questions

Harvard Bioscience's stock was trading at $2.11 at the start of the year. Since then, HBIO shares have decreased by 77.5% and is now trading at $0.4740.

Harvard Bioscience, Inc. (NASDAQ:HBIO) released its quarterly earnings results on Tuesday, November, 2nd. The medical instruments supplier reported $0.06 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.06. The medical instruments supplier had revenue of $29.66 million for the quarter, compared to analysts' expectations of $28.10 million. Harvard Bioscience had a negative net margin of 64.68% and a negative trailing twelve-month return on equity of 5.64%.

Harvard Bioscience subsidiaries include Data Sciences International.

Top institutional shareholders of Harvard Bioscience include AMH Equity Ltd (7.94%), Harvey Partners LLC (4.81%), Geode Capital Management LLC (1.00%) and Pasadena Private Wealth LLC (0.55%).
View institutional ownership trends
.

Shares of HBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Harvard Bioscience investors own include YETI (YETI), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Alphabet (GOOG), Stag Industrial (STAG) and Tesla (TSLA).

Company Calendar

Last Earnings
11/02/2021
Today
9/03/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
INSTRU - SCIENTFC
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:HBIO
CIK
1123494
Employees
490
Year Founded
1901

Price Target and Rating

High Price Target
$3.00
Low Price Target
$3.00
Potential Upside/Downside
+532.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.30)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.40 million
Net Margins
-64.68%
Pretax Margin
-64.17%
Return on Equity
-5.64%
Return on Assets
-2.15%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.81
Quick Ratio
0.41

Sales & Book Value

Annual Sales
$88.75 million
Price / Sales
0.24
Cash Flow
$0.10 per share
Price / Cash Flow
4.90
Book Value
$0.35 per share
Price / Book
1.35

Miscellaneous

Outstanding Shares
44,531,000
Free Float
40,301,000
Market Cap
$21.11 million
Optionable
Optionable
Beta
1.54

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:HBIO) was last updated on 9/3/2025 by MarketBeat.com Staff
From Our Partners